{"id":"lokelma-oral-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lokelma (sodium zirconium cyclosilicate) is an inorganic, non-absorbed potassium binder that works in the distal colon by exchanging sodium for potassium ions, thereby reducing serum potassium concentration. The drug is not systemically absorbed and potassium is eliminated in feces, making it suitable for chronic management of hyperkalemia.","oneSentence":"Lokelma is a potassium binder that selectively captures and removes potassium from the gastrointestinal tract to lower serum potassium levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:35.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperkalemia (elevated serum potassium)"}]},"trialDetails":[{"nctId":"NCT03813407","phase":"PHASE3","title":"An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-02","conditions":"Hyperkalaemia","enrollment":140},{"nctId":"NCT04585542","phase":"PHASE4","title":"Comparison of Potassium Binders in the ER","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-10-20","conditions":"Acute Hyperkalemia, Oral Potassium Binders","enrollment":37},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT05004363","phase":"PHASE3","title":"Lokelma for RAAS Maximisation in CKD & Heart Failure.","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2022-01-19","conditions":"Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction, Hyperkalemia","enrollment":130},{"nctId":"NCT04727840","phase":"PHASE1","title":"Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-15","conditions":"Chronic Kidney Diseases, Hyperkalemia","enrollment":20},{"nctId":"NCT04063930","phase":"PHASE4","title":"The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-10","conditions":"Type 2 Diabetes Mellitus With Kidney Complications","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo"],"phase":"phase_3","status":"active","brandName":"Lokelma Oral Product","genericName":"Lokelma Oral Product","companyName":"St George's, University of London","companyId":"st-george-s-university-of-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lokelma is a potassium binder that selectively captures and removes potassium from the gastrointestinal tract to lower serum potassium levels. Used for Hyperkalemia (elevated serum potassium).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}